Resource Guide: Long term outcome of Pigmentary Maculopathy after Elmiron

Below is a working bibliography of trusted health, pharmacovigilance, and legal-analysis sources, compiled for open research.

Recommended deep-dive

Long term outcome of Pigmentary Maculopathy after Elmiron

A focused review of background, context, and source material on this subject.

European Medicines Agency (EMA)

Reference: European Medicines Agency (EMA)

Authoritative source for clinical, regulatory, and public-health background reading.

Centers for Disease Control and Prevention (CDC)

Reference: Centers for Disease Control and Prevention (CDC)

Authoritative source for clinical, regulatory, and public-health background reading.